Literature DB >> 17999084

Relationship between two sequence variations in the gene for peroxisome proliferator-activated receptor-gamma and plasma homocysteine concentration. Health in men study.

Jonathan Golledge1, Paul E Norman.   

Abstract

The concentration of circulating homocysteine has been associated with a variety of diseases, including myocardial infarction, stroke, venous thrombosis and cognitive decline. Genetic variation has been demonstrated to play an important role in determining plasma homocysteine, however, the genes involved are incompletely understood. Ligation of the transcription factor peroxisome proliferator-activated gamma (PPARG) has been demonstrated to lower plasma homocysteine. We examined the association of two sequence variations in PPARG with plasma concentrations of homocysteine in a population-based study of 3,875 elderly men. PPARG c.34G > C and PPARG c.1347C > T sequence variations were determined by real-time quantitative PCR and related to logarithm transformed homocysteine concentrations using linear regression, adjusting for the co-variants age, renal function, smoking, coronary heart disease, waist to hip ratio, diabetes, hypertension and MTHFR g.677C > T sequence variation. Median plasma homocysteine concentration was 10% higher in men who were homozygous for the rare allelic variation in PPARG c.34G > C and PPARG c.1347C > T by comparison to those who had wild type sequence variation. PPARG c.1347C > T (beta = 0.038, P = 0.01 recessive model; beta = 0.036, P = 0.02 dominant model) sequence variation was positively associated with homocysteine concentration after adjusting for co-variants. The two PPARG sequence variations were in linkage disequilibrium and the common haplotype was associated with lower plasma homocysteine (P = 0.005). Our findings demonstrate a new genotypic association with plasma homocysteine. Replication will be required in other cohorts.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17999084     DOI: 10.1007/s00439-007-0446-8

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  32 in total

1.  Major gene evidence after MTHFR-segregation analysis of serum homocysteine in families of patients undergoing coronary arteriography.

Authors:  Sun Ha Jee; Kyung Soon Song; Won Heum Shim; Hyun Kyung Kim; Il Suh; Jung Yong Park; So Young Won; Terri H Beaty
Journal:  Hum Genet       Date:  2002-06-29       Impact factor: 4.132

2.  Homocysteine and the risk of ischemic stroke in a triethnic cohort: the NOrthern MAnhattan Study.

Authors:  Ralph L Sacco; Kishlay Anand; Hye-Seung Lee; Bernadette Boden-Albala; Sally Stabler; Robert Allen; Myunghee C Paik
Journal:  Stroke       Date:  2004-09-02       Impact factor: 7.914

3.  Estimates of heritability of plasma homocyst(e)ine levels in aging adult male twins.

Authors:  T Reed; M R Malinow; J C Christian; B Upson
Journal:  Clin Genet       Date:  1991-06       Impact factor: 4.438

4.  Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis.

Authors: 
Journal:  JAMA       Date:  2002 Oct 23-30       Impact factor: 56.272

5.  Hyperhomocysteinemia is inversely related with left ventricular ejection fraction and predicts cardiovascular mortality in high-risk coronary artery disease hypertensives.

Authors:  Maurizio Cesari; Mario Zanchetta; Alberto Burlina; Luigi Pedon; Giuseppe Maiolino; Daniele Sticchi; Achille C Pessina; Gian Paolo Rossi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-11-04       Impact factor: 8.311

6.  Novel genomic loci influencing plasma homocysteine levels.

Authors:  Iftikhar J Kullo; Keyue Ding; Eric Boerwinkle; Stephen T Turner; Thomas H Mosley; Sharon L R Kardia; Mariza de Andrade
Journal:  Stroke       Date:  2006-06-01       Impact factor: 7.914

7.  Peroxisome proliferator-activated receptor gamma C161-->T polymorphism and coronary artery disease.

Authors:  X L Wang; J Oosterhof; N Duarte
Journal:  Cardiovasc Res       Date:  1999-12       Impact factor: 10.787

8.  Rosiglitazone reduces serum homocysteine levels, smooth muscle proliferation, and intimal hyperplasia in Sprague-Dawley rats fed a high methionine diet.

Authors:  Subramanyam N Murthy; Demian F Obregon; Natasha N Chattergoon; Neil A Fonseca; Debasis Mondal; Jeffrey B Dunne; Jose G Diez; James R Jeter; Philip J Kadowitz; Krishna C Agrawal; Dennis B McNamara; Vivian A Fonseca
Journal:  Metabolism       Date:  2005-05       Impact factor: 8.694

9.  A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity.

Authors:  S S Deeb; L Fajas; M Nemoto; J Pihlajamäki; L Mykkänen; J Kuusisto; M Laakso; W Fujimoto; J Auwerx
Journal:  Nat Genet       Date:  1998-11       Impact factor: 38.330

10.  Population based randomised controlled trial on impact of screening on mortality from abdominal aortic aneurysm.

Authors:  Paul E Norman; Konrad Jamrozik; Michael M Lawrence-Brown; Max T Q Le; Carole A Spencer; Raywin J Tuohy; Richard W Parsons; James A Dickinson
Journal:  BMJ       Date:  2004-11-15
View more
  6 in total

1.  Association of an allele on chromosome 9 and abdominal aortic aneurysm.

Authors:  Erik Biros; Matthew Cooper; Lyle J Palmer; Philip J Walker; Paul E Norman; Jonathan Golledge
Journal:  Atherosclerosis       Date:  2010-06-15       Impact factor: 5.162

2.  Association and interaction of PPAR-complex gene variants with latent traits of left ventricular diastolic function.

Authors:  Jyh-Ming Jimmy Juang; Lisa de Las Fuentes; Alan D Waggoner; C Charles Gu; Víctor G Dávila-Román
Journal:  BMC Med Genet       Date:  2010-04-28       Impact factor: 2.103

3.  Homocysteine and Hypertension in Diabetes: Does PPARgamma Have a Regulatory Role?

Authors:  Utpal Sen; Suresh C Tyagi
Journal:  PPAR Res       Date:  2010-06-29       Impact factor: 4.964

4.  Association of PPARgamma allelic variation, osteoprotegerin and abdominal aortic aneurysm.

Authors:  Corey S Moran; Paula Clancy; Erik Biros; Bernardo Blanco-Martin; Pamela McCaskie; Lyle J Palmer; Danny Coomans; Paul E Norman; Jonathan Golledge
Journal:  Clin Endocrinol (Oxf)       Date:  2009-04-25       Impact factor: 3.478

5.  Meta-analysis on MTHFR polymorphism and lung cancer susceptibility in East Asian populations.

Authors:  Xue-DE Zhang; Yan-Ting Li; Shuan-Ying Yang; Wei Li
Journal:  Biomed Rep       Date:  2013-02-25

6.  Explore the Role of the rs1801133-PPARG Pathway in the H-type Hypertension.

Authors:  Xiuwen Liang; Tingting He; Lihong Gao; Libo Wei; Di Rong; Yu Zhang; Yu Liu
Journal:  PPAR Res       Date:  2022-03-20       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.